http://new.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Fri, 07 Aug 2026 16:07:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://new.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++LIGAND+PHARMACEUTICALS++++For%3A+Jun+30/26891028.html si-local-file:///var/storage/secattach/20260807/26891028.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++LIGAND+PHARMACEUTICALS++++For%3A+Jun+30/26891028.html Fri, 07 Aug 2026 16:07:00 -0400 LGND O.00091944 http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++LIGAND+PHARMACEUTICALS++++For%3A+Jun+30/26891028.html si-local-file:///var/storage/secattach/20260807/26891028.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++LIGAND+PHARMACEUTICALS++++For%3A+Jun+30/26891028.html Fri, 07 Aug 2026 16:07:00 -0400 LGND O.00091944 http://www.streetinsider.com/Analyst+PT+Change/Ligand+Pharma+%28LGND%29+PT+Raised+to+%24345+at+RBC+Capital/26887486.html RBC Capital analyst Douglas Miehm raised the price target on Ligand Pharma (NASDAQ: LGND) to $345.00 (from $340.00) while maintaining a Outperform rating. http://www.streetinsider.com/Analyst+PT+Change/Ligand+Pharma+%28LGND%29+PT+Raised+to+%24345+at+RBC+Capital/26887486.html Fri, 07 Aug 2026 07:21:37 -0400 LGND http://www.streetinsider.com/Earnings/Ligand+Pharma+%28LGND%29+Tops+Q2+EPS+by+42c/26878679.html <p>Ligand Pharma (NASDAQ: LGND) reported Q2 EPS of $2.37, $0.42 better than the analyst estimate of $1.95. Revenue for the quarter came in at $83.7 million versus the consensus estimate of $62.93 million.</p><p>For earnings history and earnings-related data on Ligand Pharma (LGND) <a href="http://www.streetinsider.com/ec_earnings.php?q=LGND">click here</a>.</p> http://www.streetinsider.com/Earnings/Ligand+Pharma+%28LGND%29+Tops+Q2+EPS+by+42c/26878679.html Thu, 06 Aug 2026 07:17:27 -0400 LGND http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++LIGAND+PHARMACEUTICALS++++For%3A+Aug+06/26878500.html si-local-file:///var/storage/secattach/20260806/26878500.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++LIGAND+PHARMACEUTICALS++++For%3A+Aug+06/26878500.html Thu, 06 Aug 2026 07:05:00 -0400 LGND O.00091944 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++LIGAND+PHARMACEUTICALS++++For%3A+Aug+06/26878500.html si-local-file:///var/storage/secattach/20260806/26878500.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++LIGAND+PHARMACEUTICALS++++For%3A+Aug+06/26878500.html Thu, 06 Aug 2026 07:05:00 -0400 LGND O.00091944 http://www.streetinsider.com/Press+Releases/Ligand+Reports+Second+Quarter+2026+Financial+Results/26878379.html <p align="center"><em>Second quarter performance driven by strong year-over-year royalty revenue growth of 32%</em></p> <p align="center"><em>Raises Low End of 2026 Adjusted EPS Guidance; Revenue Guidance Unchanged</em></p> <p align="center"><em>Conference call begins at 8:30 a.m. Eastern Time today</em></p> <p align="justify">JUPITER, Fla., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today reported financial results for the three and six months ended June 30, 2026, and provided an operating forecast and business update. Ligand management will host a conference call and webcast today at 8:30 a.m. Eastern Time to discuss the results and answer questions. </p> http://www.streetinsider.com/Press+Releases/Ligand+Reports+Second+Quarter+2026+Financial+Results/26878379.html Thu, 06 Aug 2026 07:00:00 -0400 A.06822034 A.29463264 A.50213540 LGND O.00091944 O.12972128 O.20026344 O.57162683 http://www.streetinsider.com/Press+Releases/Ligand+Reports+Second+Quarter+2026+Financial+Results/26878379.html <p align="center"><em>Second quarter performance driven by strong year-over-year royalty revenue growth of 32%</em></p> <p align="center"><em>Raises Low End of 2026 Adjusted EPS Guidance; Revenue Guidance Unchanged</em></p> <p align="center"><em>Conference call begins at 8:30 a.m. Eastern Time today</em></p> <p align="justify">JUPITER, Fla., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today reported financial results for the three and six months ended June 30, 2026, and provided an operating forecast and business update. Ligand management will host a conference call and webcast today at 8:30 a.m. Eastern Time to discuss the results and answer questions. </p> http://www.streetinsider.com/Press+Releases/Ligand+Reports+Second+Quarter+2026+Financial+Results/26878379.html Thu, 06 Aug 2026 07:00:00 -0400 A.06822034 A.29463264 A.50213540 LGND O.00091944 O.12972128 O.20026344 O.57162683 http://www.streetinsider.com/Press+Releases/Ligand+Reports+Second+Quarter+2026+Financial+Results/26878379.html <p align="center"><em>Second quarter performance driven by strong year-over-year royalty revenue growth of 32%</em></p> <p align="center"><em>Raises Low End of 2026 Adjusted EPS Guidance; Revenue Guidance Unchanged</em></p> <p align="center"><em>Conference call begins at 8:30 a.m. Eastern Time today</em></p> <p align="justify">JUPITER, Fla., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today reported financial results for the three and six months ended June 30, 2026, and provided an operating forecast and business update. Ligand management will host a conference call and webcast today at 8:30 a.m. Eastern Time to discuss the results and answer questions. </p> http://www.streetinsider.com/Press+Releases/Ligand+Reports+Second+Quarter+2026+Financial+Results/26878379.html Thu, 06 Aug 2026 07:00:00 -0400 A.06822034 A.29463264 A.50213540 LGND O.00091944 O.12972128 O.20026344 O.57162683 http://www.streetinsider.com/Press+Releases/Ligand+Reports+Second+Quarter+2026+Financial+Results/26878379.html <p align="center"><em>Second quarter performance driven by strong year-over-year royalty revenue growth of 32%</em></p> <p align="center"><em>Raises Low End of 2026 Adjusted EPS Guidance; Revenue Guidance Unchanged</em></p> <p align="center"><em>Conference call begins at 8:30 a.m. Eastern Time today</em></p> <p align="justify">JUPITER, Fla., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today reported financial results for the three and six months ended June 30, 2026, and provided an operating forecast and business update. Ligand management will host a conference call and webcast today at 8:30 a.m. Eastern Time to discuss the results and answer questions. </p> http://www.streetinsider.com/Press+Releases/Ligand+Reports+Second+Quarter+2026+Financial+Results/26878379.html Thu, 06 Aug 2026 07:00:00 -0400 A.06822034 A.29463264 A.50213540 LGND O.00091944 O.12972128 O.20026344 O.57162683 http://www.streetinsider.com/Press+Releases/Ligand+Reports+Second+Quarter+2026+Financial+Results/26878379.html <p align="center"><em>Second quarter performance driven by strong year-over-year royalty revenue growth of 32%</em></p> <p align="center"><em>Raises Low End of 2026 Adjusted EPS Guidance; Revenue Guidance Unchanged</em></p> <p align="center"><em>Conference call begins at 8:30 a.m. Eastern Time today</em></p> <p align="justify">JUPITER, Fla., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today reported financial results for the three and six months ended June 30, 2026, and provided an operating forecast and business update. Ligand management will host a conference call and webcast today at 8:30 a.m. Eastern Time to discuss the results and answer questions. </p> http://www.streetinsider.com/Press+Releases/Ligand+Reports+Second+Quarter+2026+Financial+Results/26878379.html Thu, 06 Aug 2026 07:00:00 -0400 A.06822034 A.29463264 A.50213540 LGND O.00091944 O.12972128 O.20026344 O.57162683 http://www.streetinsider.com/Press+Releases/Ligand+Reports+Second+Quarter+2026+Financial+Results/26878379.html <p align="center"><em>Second quarter performance driven by strong year-over-year royalty revenue growth of 32%</em></p> <p align="center"><em>Raises Low End of 2026 Adjusted EPS Guidance; Revenue Guidance Unchanged</em></p> <p align="center"><em>Conference call begins at 8:30 a.m. Eastern Time today</em></p> <p align="justify">JUPITER, Fla., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today reported financial results for the three and six months ended June 30, 2026, and provided an operating forecast and business update. Ligand management will host a conference call and webcast today at 8:30 a.m. Eastern Time to discuss the results and answer questions. </p> http://www.streetinsider.com/Press+Releases/Ligand+Reports+Second+Quarter+2026+Financial+Results/26878379.html Thu, 06 Aug 2026 07:00:00 -0400 A.06822034 A.29463264 A.50213540 LGND O.00091944 O.12972128 O.20026344 O.57162683 http://www.streetinsider.com/Press+Releases/Ligand+Reports+Second+Quarter+2026+Financial+Results/26878379.html <p align="center"><em>Second quarter performance driven by strong year-over-year royalty revenue growth of 32%</em></p> <p align="center"><em>Raises Low End of 2026 Adjusted EPS Guidance; Revenue Guidance Unchanged</em></p> <p align="center"><em>Conference call begins at 8:30 a.m. Eastern Time today</em></p> <p align="justify">JUPITER, Fla., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today reported financial results for the three and six months ended June 30, 2026, and provided an operating forecast and business update. Ligand management will host a conference call and webcast today at 8:30 a.m. Eastern Time to discuss the results and answer questions. </p> http://www.streetinsider.com/Press+Releases/Ligand+Reports+Second+Quarter+2026+Financial+Results/26878379.html Thu, 06 Aug 2026 07:00:00 -0400 A.06822034 A.29463264 A.50213540 LGND O.00091944 O.12972128 O.20026344 O.57162683 http://www.streetinsider.com/Press+Releases/Ligand+Reports+Second+Quarter+2026+Financial+Results/26878379.html <p align="center"><em>Second quarter performance driven by strong year-over-year royalty revenue growth of 32%</em></p> <p align="center"><em>Raises Low End of 2026 Adjusted EPS Guidance; Revenue Guidance Unchanged</em></p> <p align="center"><em>Conference call begins at 8:30 a.m. Eastern Time today</em></p> <p align="justify">JUPITER, Fla., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today reported financial results for the three and six months ended June 30, 2026, and provided an operating forecast and business update. Ligand management will host a conference call and webcast today at 8:30 a.m. Eastern Time to discuss the results and answer questions. </p> http://www.streetinsider.com/Press+Releases/Ligand+Reports+Second+Quarter+2026+Financial+Results/26878379.html Thu, 06 Aug 2026 07:00:00 -0400 A.06822034 A.29463264 A.50213540 LGND O.00091944 O.12972128 O.20026344 O.57162683 http://www.streetinsider.com/Globe+Newswire/Ligand+Reports+Second+Quarter+2026+Financial+Results/26878379.html <p align="center"><em>Second quarter performance driven by strong year-over-year royalty revenue growth of 32%</em></p> <p align="center"><em>Raises Low End of 2026 Adjusted EPS Guidance; Revenue Guidance Unchanged</em></p> <p align="center"><em>Conference call begins at 8:30 a.m. Eastern Time today</em></p> <p align="justify">JUPITER, Fla., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today reported financial results for the three and six months ended June 30, 2026, and provided an operating forecast and business update. Ligand management will host a conference call and webcast today at 8:30 a.m. Eastern Time to discuss the results and answer questions. </p> http://www.streetinsider.com/Globe+Newswire/Ligand+Reports+Second+Quarter+2026+Financial+Results/26878379.html Thu, 06 Aug 2026 07:00:00 -0400 A.06822034 A.29463264 A.50213540 LGND O.00091944 O.12972128 O.20026344 O.57162683 http://www.streetinsider.com/Globe+Newswire/Ligand+Reports+Second+Quarter+2026+Financial+Results/26878379.html <p align="center"><em>Second quarter performance driven by strong year-over-year royalty revenue growth of 32%</em></p> <p align="center"><em>Raises Low End of 2026 Adjusted EPS Guidance; Revenue Guidance Unchanged</em></p> <p align="center"><em>Conference call begins at 8:30 a.m. Eastern Time today</em></p> <p align="justify">JUPITER, Fla., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today reported financial results for the three and six months ended June 30, 2026, and provided an operating forecast and business update. Ligand management will host a conference call and webcast today at 8:30 a.m. Eastern Time to discuss the results and answer questions. </p> http://www.streetinsider.com/Globe+Newswire/Ligand+Reports+Second+Quarter+2026+Financial+Results/26878379.html Thu, 06 Aug 2026 07:00:00 -0400 A.06822034 A.29463264 A.50213540 LGND O.00091944 O.12972128 O.20026344 O.57162683 http://www.streetinsider.com/Globe+Newswire/Ligand+Reports+Second+Quarter+2026+Financial+Results/26878379.html <p align="center"><em>Second quarter performance driven by strong year-over-year royalty revenue growth of 32%</em></p> <p align="center"><em>Raises Low End of 2026 Adjusted EPS Guidance; Revenue Guidance Unchanged</em></p> <p align="center"><em>Conference call begins at 8:30 a.m. Eastern Time today</em></p> <p align="justify">JUPITER, Fla., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today reported financial results for the three and six months ended June 30, 2026, and provided an operating forecast and business update. Ligand management will host a conference call and webcast today at 8:30 a.m. Eastern Time to discuss the results and answer questions. </p> http://www.streetinsider.com/Globe+Newswire/Ligand+Reports+Second+Quarter+2026+Financial+Results/26878379.html Thu, 06 Aug 2026 07:00:00 -0400 A.06822034 A.29463264 A.50213540 LGND O.00091944 O.12972128 O.20026344 O.57162683 http://www.streetinsider.com/Globe+Newswire/Ligand+Reports+Second+Quarter+2026+Financial+Results/26878379.html <p align="center"><em>Second quarter performance driven by strong year-over-year royalty revenue growth of 32%</em></p> <p align="center"><em>Raises Low End of 2026 Adjusted EPS Guidance; Revenue Guidance Unchanged</em></p> <p align="center"><em>Conference call begins at 8:30 a.m. Eastern Time today</em></p> <p align="justify">JUPITER, Fla., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today reported financial results for the three and six months ended June 30, 2026, and provided an operating forecast and business update. Ligand management will host a conference call and webcast today at 8:30 a.m. Eastern Time to discuss the results and answer questions. </p> http://www.streetinsider.com/Globe+Newswire/Ligand+Reports+Second+Quarter+2026+Financial+Results/26878379.html Thu, 06 Aug 2026 07:00:00 -0400 A.06822034 A.29463264 A.50213540 LGND O.00091944 O.12972128 O.20026344 O.57162683 http://www.streetinsider.com/Globe+Newswire/Ligand+Reports+Second+Quarter+2026+Financial+Results/26878379.html <p align="center"><em>Second quarter performance driven by strong year-over-year royalty revenue growth of 32%</em></p> <p align="center"><em>Raises Low End of 2026 Adjusted EPS Guidance; Revenue Guidance Unchanged</em></p> <p align="center"><em>Conference call begins at 8:30 a.m. Eastern Time today</em></p> <p align="justify">JUPITER, Fla., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today reported financial results for the three and six months ended June 30, 2026, and provided an operating forecast and business update. Ligand management will host a conference call and webcast today at 8:30 a.m. Eastern Time to discuss the results and answer questions. </p> http://www.streetinsider.com/Globe+Newswire/Ligand+Reports+Second+Quarter+2026+Financial+Results/26878379.html Thu, 06 Aug 2026 07:00:00 -0400 A.06822034 A.29463264 A.50213540 LGND O.00091944 O.12972128 O.20026344 O.57162683 http://www.streetinsider.com/Globe+Newswire/Ligand+Reports+Second+Quarter+2026+Financial+Results/26878379.html <p align="center"><em>Second quarter performance driven by strong year-over-year royalty revenue growth of 32%</em></p> <p align="center"><em>Raises Low End of 2026 Adjusted EPS Guidance; Revenue Guidance Unchanged</em></p> <p align="center"><em>Conference call begins at 8:30 a.m. Eastern Time today</em></p> <p align="justify">JUPITER, Fla., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today reported financial results for the three and six months ended June 30, 2026, and provided an operating forecast and business update. Ligand management will host a conference call and webcast today at 8:30 a.m. Eastern Time to discuss the results and answer questions. </p> http://www.streetinsider.com/Globe+Newswire/Ligand+Reports+Second+Quarter+2026+Financial+Results/26878379.html Thu, 06 Aug 2026 07:00:00 -0400 A.06822034 A.29463264 A.50213540 LGND O.00091944 O.12972128 O.20026344 O.57162683 http://www.streetinsider.com/Globe+Newswire/Ligand+Reports+Second+Quarter+2026+Financial+Results/26878379.html <p align="center"><em>Second quarter performance driven by strong year-over-year royalty revenue growth of 32%</em></p> <p align="center"><em>Raises Low End of 2026 Adjusted EPS Guidance; Revenue Guidance Unchanged</em></p> <p align="center"><em>Conference call begins at 8:30 a.m. Eastern Time today</em></p> <p align="justify">JUPITER, Fla., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today reported financial results for the three and six months ended June 30, 2026, and provided an operating forecast and business update. Ligand management will host a conference call and webcast today at 8:30 a.m. Eastern Time to discuss the results and answer questions. </p> http://www.streetinsider.com/Globe+Newswire/Ligand+Reports+Second+Quarter+2026+Financial+Results/26878379.html Thu, 06 Aug 2026 07:00:00 -0400 A.06822034 A.29463264 A.50213540 LGND O.00091944 O.12972128 O.20026344 O.57162683 http://www.streetinsider.com/Globe+Newswire/Ligand+Reports+Second+Quarter+2026+Financial+Results/26878379.html <p align="center"><em>Second quarter performance driven by strong year-over-year royalty revenue growth of 32%</em></p> <p align="center"><em>Raises Low End of 2026 Adjusted EPS Guidance; Revenue Guidance Unchanged</em></p> <p align="center"><em>Conference call begins at 8:30 a.m. Eastern Time today</em></p> <p align="justify">JUPITER, Fla., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today reported financial results for the three and six months ended June 30, 2026, and provided an operating forecast and business update. Ligand management will host a conference call and webcast today at 8:30 a.m. Eastern Time to discuss the results and answer questions. </p> http://www.streetinsider.com/Globe+Newswire/Ligand+Reports+Second+Quarter+2026+Financial+Results/26878379.html Thu, 06 Aug 2026 07:00:00 -0400 A.06822034 A.29463264 A.50213540 LGND O.00091944 O.12972128 O.20026344 O.57162683 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++LIGAND+PHARMACEUTICALS++++For%3A+Aug+03++Filed+by%3A+Reardon+Andrew/26868377.html si-local-file:///var/storage/secattach/20260804/26868377.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++LIGAND+PHARMACEUTICALS++++For%3A+Aug+03++Filed+by%3A+Reardon+Andrew/26868377.html Tue, 04 Aug 2026 18:43:00 -0400 LGND O.00091944 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++LIGAND+PHARMACEUTICALS++++For%3A+Aug+03++Filed+by%3A+Reardon+Andrew/26868377.html si-local-file:///var/storage/secattach/20260804/26868377.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++LIGAND+PHARMACEUTICALS++++For%3A+Aug+03++Filed+by%3A+Reardon+Andrew/26868377.html Tue, 04 Aug 2026 18:43:00 -0400 LGND O.00091944 http://www.streetinsider.com/Analyst+PT+Change/Ligand+Pharma+%28LGND%29+PT+Raised+to+%24326+at+Oppenheimer/26852744.html <p>Oppenheimer analyst Leland Gershell raised the price target on Ligand Pharma (NASDAQ: LGND) to $326.00 (from $285.00) while maintaining a Outperform rating.</p><p>The analyst comments "We have rebuilt our LGND model following the recent transfer of coverage. Our new model reflects the XOMA Royalty acquisition which closed July 14. We now project 2026-28 total revenue of $289M, 382M, and 457M vs. consensus $290M, 375M, and 441M, resp. We now project 2026-28 adj. EPS of $9.14, 12.03, and 13.99 vs. cons $9.14, 11.60, and 13.82, resp. We reiterate Outperform and raise our PT to $326 from $285."</p> http://www.streetinsider.com/Analyst+PT+Change/Ligand+Pharma+%28LGND%29+PT+Raised+to+%24326+at+Oppenheimer/26852744.html Mon, 03 Aug 2026 05:51:17 -0400 LGND